SI3357922T1 - 2-((5-(1-(3-(metilsulfonil)propil)piperidin-4-il)piridin-2-il)amino) pirido(2,3-D)pirimidin-7(8H)-on derivati in sorodne spojine kot CDK4 inhibitorji za zdravljenje tumorjev - Google Patents
2-((5-(1-(3-(metilsulfonil)propil)piperidin-4-il)piridin-2-il)amino) pirido(2,3-D)pirimidin-7(8H)-on derivati in sorodne spojine kot CDK4 inhibitorji za zdravljenje tumorjevInfo
- Publication number
- SI3357922T1 SI3357922T1 SI201630949T SI201630949T SI3357922T1 SI 3357922 T1 SI3357922 T1 SI 3357922T1 SI 201630949 T SI201630949 T SI 201630949T SI 201630949 T SI201630949 T SI 201630949T SI 3357922 T1 SI3357922 T1 SI 3357922T1
- Authority
- SI
- Slovenia
- Prior art keywords
- pyrido
- methylsulfonyl
- pyrimidin
- piperidin
- pyridin
- Prior art date
Links
- SBUJWIRPWUWGPJ-UHFFFAOYSA-N 2-[[5-[1-(3-methylsulfonylpropyl)piperidin-4-yl]pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one Chemical class CS(=O)(=O)CCCN1CCC(CC1)C=1C=CC(=NC=1)NC=1N=CC2=C(N=1)NC(C=C2)=O SBUJWIRPWUWGPJ-UHFFFAOYSA-N 0.000 title 1
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510646418.4A CN105130986B (zh) | 2015-09-30 | 2015-09-30 | 嘧啶或吡啶并吡啶酮类化合物及其应用 |
| PCT/CN2016/084056 WO2017054484A1 (zh) | 2015-09-30 | 2016-05-31 | 嘧啶或吡啶并吡啶酮类化合物及其应用 |
| EP16850109.6A EP3357922B1 (en) | 2015-09-30 | 2016-05-31 | 2-((5-(1-(3-(methylsulfonyl)propyl)piperidin-4-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8h)-one derivatives and related compounds as cdk4 inhibitors for treating tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3357922T1 true SI3357922T1 (sl) | 2020-12-31 |
Family
ID=54716613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201630949T SI3357922T1 (sl) | 2015-09-30 | 2016-05-31 | 2-((5-(1-(3-(metilsulfonil)propil)piperidin-4-il)piridin-2-il)amino) pirido(2,3-D)pirimidin-7(8H)-on derivati in sorodne spojine kot CDK4 inhibitorji za zdravljenje tumorjev |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10183941B2 (sl) |
| EP (1) | EP3357922B1 (sl) |
| JP (1) | JP6556369B2 (sl) |
| CN (1) | CN105130986B (sl) |
| AU (1) | AU2016333188B2 (sl) |
| CA (1) | CA3000548C (sl) |
| DK (1) | DK3357922T3 (sl) |
| ES (1) | ES2828984T3 (sl) |
| HR (1) | HRP20201727T1 (sl) |
| HU (1) | HUE052454T2 (sl) |
| PL (1) | PL3357922T3 (sl) |
| PT (1) | PT3357922T (sl) |
| SI (1) | SI3357922T1 (sl) |
| WO (1) | WO2017054484A1 (sl) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106795159B (zh) * | 2015-04-22 | 2018-12-28 | 江苏恒瑞医药股份有限公司 | 一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法 |
| WO2017101763A1 (en) | 2015-12-13 | 2017-06-22 | Hangzhou Innogate Pharma Co., Ltd. | Heterocycles useful as anti-cancer agents |
| CN106083844B (zh) * | 2016-06-05 | 2017-11-10 | 陈志明 | 一种制备抗乳腺癌药物帕博西尼中间体的方法 |
| TWI749126B (zh) * | 2016-12-16 | 2021-12-11 | 大陸商基石藥業（蘇州）有限公司 | Cdk4/6抑制劑 |
| WO2019015593A1 (zh) * | 2017-07-19 | 2019-01-24 | 江苏奥赛康药业股份有限公司 | 嘧啶并吡啶酮或者吡啶并吡啶酮类化合物及其应用 |
| CN112292379B (zh) * | 2018-06-13 | 2022-03-04 | 基石药业（苏州）有限公司 | 吡啶并吡啶酮衍生物的盐型及晶型 |
| CN109320511A (zh) * | 2018-10-26 | 2019-02-12 | 广安凯特制药有限公司 | 一种高纯度帕博西尼中间体产品及其制备方法 |
| WO2021108803A1 (en) | 2019-11-26 | 2021-06-03 | Theravance Biopharma R&D Ip, Llc | Fused pyrimidine pyridinone compounds as jak inhibitors |
| EP4110782A1 (en) * | 2020-02-28 | 2023-01-04 | Fochon Biosciences, Ltd. | Compounds as cdk2/4/6 inhibitors |
| TW202237585A (zh) | 2020-11-27 | 2022-10-01 | 瑞士商瑞森製藥公司 | Ｃｄｋ抑制劑 |
| CN112457311B (zh) * | 2020-12-04 | 2022-07-12 | 江苏豪森药业集团有限公司 | 一种含有氯溴吡咯嘧啶酮结构化合物的制备方法 |
| CN112778303A (zh) * | 2020-12-31 | 2021-05-11 | 武汉九州钰民医药科技有限公司 | Cdk4/6激酶抑制剂shr6390的制备方法 |
| WO2022149057A1 (en) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| CN116063307A (zh) * | 2021-10-29 | 2023-05-05 | 中国药科大学 | Shp2与cdk4/6双靶点抑制化合物合成及其制备方法与应用 |
| CN114751909B (zh) * | 2022-03-17 | 2023-10-27 | 杭州福斯特药业有限公司 | 一种瑞博西尼中间体的制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MEP46108A (en) * | 2002-01-22 | 2011-02-10 | Warner Lambert Co | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES |
| US8058283B2 (en) * | 2006-01-31 | 2011-11-15 | Hoffmann-La Roche Inc. | 7H-pyrido[3,4-D]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors |
| AR060635A1 (es) * | 2006-04-27 | 2008-07-02 | Banyu Pharma Co Ltd | Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer |
| US20080114007A1 (en) * | 2006-10-31 | 2008-05-15 | Player Mark R | 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase |
| TW200942537A (en) * | 2008-02-01 | 2009-10-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
| CN103288824B (zh) * | 2012-02-23 | 2015-12-09 | 上海师范大学 | 四氢吡啶并吡啶酮衍生物、其制备方法及应用 |
| US9493454B2 (en) * | 2012-09-26 | 2016-11-15 | Tolero Pharmaceuticals, Inc. | Multiple kinase pathway inhibitors |
| WO2014183520A1 (zh) * | 2013-05-17 | 2014-11-20 | 上海恒瑞医药有限公司 | 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 |
| AU2015296322B2 (en) * | 2014-07-26 | 2019-09-19 | Sunshine Lake Pharma Co., Ltd. | 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof |
| CN106795159B (zh) * | 2015-04-22 | 2018-12-28 | 江苏恒瑞医药股份有限公司 | 一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法 |
-
2015
- 2015-09-30 CN CN201510646418.4A patent/CN105130986B/zh active Active
-
2016
- 2016-05-31 PT PT168501096T patent/PT3357922T/pt unknown
- 2016-05-31 PL PL16850109T patent/PL3357922T3/pl unknown
- 2016-05-31 ES ES16850109T patent/ES2828984T3/es active Active
- 2016-05-31 AU AU2016333188A patent/AU2016333188B2/en active Active
- 2016-05-31 WO PCT/CN2016/084056 patent/WO2017054484A1/zh active Application Filing
- 2016-05-31 SI SI201630949T patent/SI3357922T1/sl unknown
- 2016-05-31 DK DK16850109.6T patent/DK3357922T3/da active
- 2016-05-31 EP EP16850109.6A patent/EP3357922B1/en active Active
- 2016-05-31 HU HUE16850109A patent/HUE052454T2/hu unknown
- 2016-05-31 US US15/764,884 patent/US10183941B2/en active Active
- 2016-05-31 HR HRP20201727TT patent/HRP20201727T1/hr unknown
- 2016-05-31 JP JP2018536324A patent/JP6556369B2/ja active Active
- 2016-05-31 CA CA3000548A patent/CA3000548C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HK1251547A1 (en) | 2019-02-01 |
| CA3000548A1 (en) | 2017-04-06 |
| EP3357922B1 (en) | 2020-08-26 |
| ES2828984T3 (es) | 2021-05-28 |
| AU2016333188B2 (en) | 2018-10-25 |
| EP3357922A1 (en) | 2018-08-08 |
| WO2017054484A1 (zh) | 2017-04-06 |
| CN105130986A (zh) | 2015-12-09 |
| DK3357922T3 (da) | 2020-11-02 |
| US10183941B2 (en) | 2019-01-22 |
| HUE052454T2 (hu) | 2021-04-28 |
| HRP20201727T1 (hr) | 2020-12-25 |
| US20180297995A1 (en) | 2018-10-18 |
| JP2018534352A (ja) | 2018-11-22 |
| AU2016333188A1 (en) | 2018-05-17 |
| CN105130986B (zh) | 2017-07-18 |
| JP6556369B2 (ja) | 2019-08-07 |
| PL3357922T3 (pl) | 2021-02-08 |
| PT3357922T (pt) | 2020-10-29 |
| CA3000548C (en) | 2020-09-22 |
| EP3357922A4 (en) | 2019-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3357922T1 (sl) | 2-((5-(1-(3-(metilsulfonil)propil)piperidin-4-il)piridin-2-il)amino) pirido(2,3-D)pirimidin-7(8H)-on derivati in sorodne spojine kot CDK4 inhibitorji za zdravljenje tumorjev | |
| IL277576A (en) | Mutated pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | |
| IL265918A (en) | Pyrazolo [1,5– A] compounds Pyridine is converted as RET kinase inhibitors | |
| IL289793A (en) | Heterocyclic compounds as ret kinase inhibitors | |
| ZA201800771B (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| RS63609B1 (sr) | Heterociklična jedinjenja kao inhibitori ret kinaze | |
| IL242170B (en) | Derivatives of 3-(2-aminopyrimidine-4yl)-5-(3-hydroxypropynyl)-h1-pyrrolo[2,3-pyridine as nickel inhibitors for cancer treatment | |
| IL282087B1 (en) | History of 4-(imidazo[2,1-a]pyridin-3-yl)-benzamide for the treatment of pruritus | |
| PT3484892T (pt) | Derivados de 1,2,4-triazolo-[3,4-b]-1,3,4-tiadiazole | |
| AU2024203236A1 (en) | Heterocyclic compounds as RET kinase inhibitors | |
| HK1260208A1 (en) | Heterocyclic compounds as ret kinase inhibitors |